Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters

Publication year range
1.
Rev. Asoc. Odontol. Argent ; 110(2): 1100851, may.-ago. 2022.
Article in Spanish | LILACS | ID: biblio-1419080

ABSTRACT

La mucormicosis es una infección fúngica rara, con alta morbilidad y mortalidad. Se presenta principalmente en pa- cientes con diabetes mellitus no controlada, inmunocompro- metidos, con tratamiento crónicos con esteroides, entre otros. Actualmente, se cree que la pandemia de COVID-19 y los tratamientos con corticosteroides podrían estar implicados en el aumento de casos de esta micosis. Este hongo invade el sistema vascular, ocluyendo el flujo sanguíneo arterial y generando una rápida trombosis e isque- mia, lo que provoca la necrosis de los tejidos duros y blandos, con invasión rápida a los tejidos circundantes. Hay varias formas clínicas. En la cavidad bucal se presenta la variante rino-orbito-cerebral, que afecta el paladar en forma de lesión eritematosa o grisácea que puede progresar hacia la formación de una masa necrótica o ulceración con muy escaso sangrado de mucosa. Se manifiesta con síntomas típicos de una rinosinusitis con fiebre y dolor en las piezas dentarias superiores. El tratamiento consta de tres pilares fundamentales: el diagnóstico, un manejo adecuado de las comorbilidades y la combinación de las terapias antifúngica y quirúrgica. Desde el año 2020, la mucormicosis asociada a COVID-19 pasó a ser un evento de notificación obligatoria inmediata al Sistema Nacional de Vigilancia de la Salud (SNVS2.0) me- diante el Sistema Integrado de Información Sanitaria Argen- tina (SISA). Es importante destacar que se han reportado casos de mu- cormicosis luego de extracciones dentales; lo que impulsa a afianzar los conocimientos sobre esta enfermedad, extremar las medidas preventivas e incentivar el diagnóstico precoz en la atención odontológica, debido a la rapidez en la evolución de la patología (AU))


Mucormycosis is a rare fungal infection, with high mor- bidity and mortality. It occurs mainly in patients with uncon- trolled diabetes mellitus, immunocompromised, on chronic treatment with steroids, among others. Currently, it is believed that the COVID-19 pandemic and the corticosteroid treatments could be one of the causes of increased cases. This fungus invades the vascular system, occluding arteri- al blood flow and generating rapid thrombosis and ischemia, which causes necrosis of hard and soft tissues, with rapid in- vasion to the surrounding tissues. There are several clinical forms. In the oral cavity, the rhino-orbito-cerebral variant presents itself affecting the pal- ate in the form of an erythematous or grayish lesion that can progress towards the formation of a necrotic mass or ulcera- tion with very little mucosal bleeding. It manifests itself with typical symptoms of rhinosinusitis, with fever and pain in the upper teeth. The treatment consists of three fundamental pillars: diag- nosis, proper management of comorbidities and the combina- tion of antifungal and surgical therapies. Since 2020, COVID-19 associated mucormycosis became an event of mandatory immediate notification to the National Health Surveillance System (SNVS2.0,) through the Argentina Integrated Health Information System (SISA). It is important to emphasize that mucormycosis cases had been reported following tooth extractions, which drives to strengthen knowledge about this disease, extreme preventive measures and encourage early diagnosis in dental care, due to the speed of the evolution of the pathology (AU))


Subject(s)
Humans , Bacterial Infections/classification , COVID-19/complications , Mucormycosis/etiology , Argentina/epidemiology , Prognosis , Signs and Symptoms , Comorbidity , Causality , Dental Care for Chronically Ill/methods , Early Diagnosis , Diabetes Mellitus/pathology , Diagnosis, Differential , Mucormycosis/pathology , Mucormycosis/prevention & control , Mucormycosis/drug therapy , Mucormycosis/epidemiology , Antifungal Agents/therapeutic use
2.
Arch. venez. pueric. pediatr ; 72(4): 139-145, oct.-dic. 2009. tab, graf
Article in Spanish | LILACS | ID: lil-588875

ABSTRACT

Existen dos avances en el manejo de la diarrea, que podrían reducir el número de muertes infantiles; el primero la formulación de Sales de Rehidratación Oral con menor concentración de glucosa y sodio; el segundo la suplementación con zinc para disminuir la duración, severidad y episodios futuros. La OMS/OPS define la diarrea aguda como la eliminación de tres o más evacuaciones intestinales líquidas o semilíquidas en 24 horas. El enterocito, como unidad funcional del intestino, posee una serie de transportadores donde ocurre el proceso de movilización de glucosa y de iones, para mantener el equilibrio eléctrico adecuado. En la evaluación del paciente la anamnesis se realiza con el fin de precisar la severidad de la diarrea y su posible causa. En el examen físico se tendrá en cuenta que esta enfermedad puede ser un signo o síntoma que se relaciona con trastornos extraintestinales. El examen de heces puede ser una herramienta útil en la investigación etiológica. Puede cuantificarse el gradiente osmótico (GAP fecal) y determinar si estamos en presencia de una diarrea osmótica o secretora. La presencia de 5 o más leucocitos fecales sugiere un proceso invasivo siendo de utilidad la realización de un recuento diferencial, si los polimorfonucleares se encuentran en 64% o más, puede ser posible recuperar bacterias en el coprocultivo. Este último tendrá indicación en algunos grupos que por edad o patología se consideran de riesgo elevados por ser no inmuno competentes. La serología para rotavirus permitiría el aislamiento rápido de pacientes infectados para limitar un brote.


Two recent advances in the management of diarrhea which could reduce child deaths are the formulation of Oral Rehydration Salts with a lower concentration of glucose and sodium, and zinc supplementation to decrease the duration and severity of future episodes. Acute diarrhea is defined by the WHO as the passage of three or more loose stools in 24 hours. The enterocyte, as the functional unit of the intestine, has a number of carriers which contribute to the mobilization process of glucose and ions to maintain the proper electrical balance. In the evaluation of the patient, the medical history will clarify the severity of diarrhea and its possible cause. During the physical examination, the fact that this disease may be a sign or symptom associated with extra intestinal disorders should be taken into account. Feces analysis may be a diagnostic tool. Osmotic gradient can be quantified (fecal GAP) to distinguish osmotic from secretory diarrhea. The presence of 5 or more fecal leukocytes suggests an invasive process and if PMNs are found in 64% or more in the differential cell count, it maybe possible to recover bacteria in a stool culture. The latter is indicated in some children considered of high risk for their low immune competence due to their age or to certain pathologies. Serology for rotavirus allows the rapid isolation of infected patients in order to limit an outbreak.


Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Child, Preschool , Child , Diarrhea/classification , Diarrhea/pathology , Fluid Therapy/methods , Bacterial Infections/classification , Dehydration/etiology , Rotavirus/pathogenicity , Serology/methods
3.
Otolaryngol Pol ; 63(6): 513-9, 2009.
Article in Polish | MEDLINE | ID: mdl-20198987

ABSTRACT

INTRODUCTION: The development of medicine, in this the new techniques and antibiotic therapy enlarged the survivability of patients in hospital. Applying antibiotics caused breakthrough in treatment stepping out in ill's group infections treated in hospital, however enlarging resistance is natural this effect, resulting from: the selection of resistant strains, the formation of new mechanisms of resistance, and/or the spreading of gene of resistance. Multidrug-resistant strains were included to emergence-pathogens group: MRSA, penicillin-resistant Streptococcus pneumoniae, VRE, Gram-negative producing beta-lactamase of type the ESBL and/or resistant to carbapenems. Emergence-pathogens occurrence leads to: therapeutic failures, the use extorts in therapy of dear medicines or with possibility of workings undesirable. The multidrug-resistant strains spread in hospital environment easily, especially on departments about high waste of medicines with the patients' simultaneously large susceptibility on infection, resulting mainly with state of reduced resistance of organism. The control of hospital infections recognize by present hospitality for the most important criterion of quality of work. AIM: Analysis of the emergence-pathogens isolated during treatment in hospital in 2005-2008, from special regard the ENT Department. MATERIAL AND METHODS: 50586 children treated in this period in hospital in which was executed 39386 bacteriological investigations, in this 6528 (12.9%) children in ENT Department in which was executed 1566 bacteriological investigations (3.98%). The diagnostics were executed according to routine microbiological procedures with qualification of resistance to antibiotics. RESULTS: Emergence-pathogens infection was confirmed at 2369 children's (4.68%) treated in Hospital, in this in ENT Department at 84 children (1.29%). The most frequent emergence-pathogens in ENT Department were Streptococcus pyogenes, Streptococcus pneumoniae penicillin-resistant and average sensitive on penicillin, Staphylococcus aureus methicillin-resistant and Rotavirus. CONCLUSIONS: Streptococcus pneumoniae penicillin-resistant and average sensitive to penicillin and Rotavirus infections are the most frequent hospital infections. The systematic microbiological supervision is indispensable in prevention the spreading of infections of the emergence-pathogens in hospital.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacterial Infections/epidemiology , Communicable Diseases, Emerging/epidemiology , Cross Infection/epidemiology , Drug Resistance, Bacterial/drug effects , Anti-Bacterial Agents/pharmacology , Bacterial Infections/classification , Bacterial Infections/drug therapy , Child , Child, Preschool , Communicable Diseases, Emerging/drug therapy , Communicable Diseases, Emerging/microbiology , Cross Infection/drug therapy , Cross Infection/microbiology , Drug Resistance, Multiple, Bacterial/drug effects , Female , Gram-Negative Bacteria/classification , Gram-Negative Bacteria/drug effects , Gram-Negative Bacteria/isolation & purification , Gram-Positive Bacteria/classification , Gram-Positive Bacteria/drug effects , Gram-Positive Bacteria/isolation & purification , Humans , Infant , Infant, Newborn , Male , Microbial Sensitivity Tests , Poland/epidemiology
4.
J Trop Pediatr ; 54(2): 125-8, 2008 Apr.
Article in English | MEDLINE | ID: mdl-17906317

ABSTRACT

To precis the aetiologies of children meningitis and the susceptibility to antibiotics of bacteria responsible for meningitis in Bangui, we conducted a prospective study between October 2004 and September 2005, at the 'Complexe Pédiatrique de Bangui', Central African Republic (CAR). Children from 1 day to 16 years with suspected meningitis and who underwent a lumbar puncture were enrolled. Gram staining, culture on chocolate blood medium, cell count, biochemistry (protein level, glucose ratio), capsular antigen detection were performed for each cerebrospinal fluid. MICs were determined by the E-test method. Four hundred and seventeen patients were enrolled during the study period; 130 were proven acute bacterial meningitis and 37 probable bacterial meningitis. Among proven bacterial meningitis, Streptococcus pneumoniae was the most common organism responsible for meningitis (62 cases, 48%) followed by Haemophilus influenzae (46 cases, 35%) and by Neisseria meningitidis and Salmonella sp. (8 cases, 6% each). Ninety-four percent and 96% of S. pneumoniae strains tested remain susceptible to benzylpenicilline and chloramphenicol, respectively. A beta-lactamase was detected in 92% of H. influenzae strains tested. However, MICs 50% and 90% for amoxicillin were found to be 1 and 4 mg/l, respectively and 33% of these strains were resistant to chloramphenicol. The global mortality rate was 35% (59/167). This mortality rate was 47% for S. pneumoniae, 33% for H. influenzae, 62% for Salmonella sp. and 13% for N. meningitidis. The probabilistic treatment with ampicillin and chloramphenicol usually administered for children meningitis in Bangui must be reconsidered particularly in cases of H. influenzae meningitis. It is of importance to reduce the presentation delays of children with suspected meningitis in Bangui. The H. influenzae b immunization would allow a dramatic reduction of meningitis cases and deaths in Central African children.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacterial Infections/classification , Meningitis, Bacterial/drug therapy , Microbial Sensitivity Tests/methods , Adolescent , Anti-Bacterial Agents/pharmacology , Bacterial Infections/mortality , Central African Republic/epidemiology , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Meningitis, Bacterial/epidemiology , Meningitis, Bacterial/microbiology , Prospective Studies
5.
Am J Rhinol ; 21(3): 286-8, 2007.
Article in English | MEDLINE | ID: mdl-17621810

ABSTRACT

BACKGROUND: Patients who undergo radiotherapy for nasopharyngeal carcinoma (NPC) tend to suffer from rhinosinusitis because irradiation causes damage to sinonasal tissue; however, their bacteriology is lacking in the literature. The aim of this study was to determine the bacteriology and antibiotic resistance in acute rhinosinusitis (ARS) of these patients. METHODS: We collected nasal purulent discharge for bacteriology and antibiotic susceptibility tests in irradiated NPC patients with ARS. Middle meatus discharge was aspirated for culture with endoscopic assistance. RESULTS: A total of 33 episodes of ARS were documented in 25 patients. Staphylococcus aureus comprised 42% of all aerobes. Thirty-six percents of aerobic isolates were Gram-negative bacilli. Peptostreptococcus micros and Veillonella spp were the most frequently isolated anaerobes. CONCLUSION: The bacteriology in irradiated NPC patients with ARS was distinctive in the following: first, the most common pathogen was S. aureus; second, frequently isolated Gram-negative bacilli and anaerobes; and third, polymicrobial infections. The beta-lactamase-producing pathogens were highly prevalent.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacterial Infections/drug therapy , Nasopharyngeal Neoplasms/radiotherapy , Rhinitis/etiology , Sinusitis/etiology , Adult , Aged , Anti-Bacterial Agents/pharmacology , Bacteria, Aerobic/classification , Bacteria, Aerobic/drug effects , Bacteria, Anaerobic/classification , Bacteria, Anaerobic/drug effects , Bacterial Infections/classification , Bacterial Infections/etiology , Female , Gram-Positive Bacteria/classification , Gram-Positive Bacteria/drug effects , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Prospective Studies , Radiotherapy/adverse effects , Rhinitis/drug therapy , Rhinitis/microbiology , Sinusitis/drug therapy , Sinusitis/microbiology
6.
Ann Biol Clin (Paris) ; 64(6): 549-64, 2006.
Article in French | MEDLINE | ID: mdl-17162258

ABSTRACT

Linezolid is a synthetic antibiotic, the first available agent in a new class of antibiotic called the oxazolidinones, whose particular mechanism of action consists in inhibiting the initiation of protein synthesis. Its spectrum of in vitro and in vivo activity includes staphylococci, streptococci, enterococci, corynebacteria and some anaerobic bacteria (Peptostreptococcus, Clostridium, and Fusobacterium). The first therapeutic results were very encouraging, leading to the marketing of the product in France in 2002. Linezolid is indicated in the treatment of pneumonia and the complicated infections of the skin. Pharmacocinetics studies have shown that linezolid has an excellent bioavailability allowing a fast relay per os. However, failures of treatment under linezolid were reported and resistant strains of staphylococci and enterococci were obtained in vitro and in vivo after therapeutic use of this antibiotic. Changes in the domain V of 23S rRNA were found in the site of fixation, the most frequent was (G out of U) in position 2576 (numbering E. coli). In a context where resistance to traditional treatments in enterococci, pneumococci and S. aureus do not cease to increase, linezolid can be regarded as a therapeutic alternative to treat the infections with Gram-positive cocci.


Subject(s)
Acetamides/therapeutic use , Anti-Infective Agents/therapeutic use , Bacterial Infections/drug therapy , Oxazolidinones/therapeutic use , Protein Synthesis Inhibitors/therapeutic use , Acetamides/pharmacokinetics , Anti-Infective Agents/pharmacokinetics , Bacteria/drug effects , Bacterial Infections/classification , Drug Resistance, Bacterial , Humans , Immunity, Innate , Linezolid , Microbial Sensitivity Tests , Oxazolidinones/pharmacokinetics
7.
Int J Urol ; 13(7): 939-46, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16882059

ABSTRACT

AIM: We propose preliminarily that acute (category I of the NIH consensus definition) and chronic prostatitis (category II) can be subcategorized into primary and recurrent diseases based on the precise analysis of the clinical course and the immunological parameters in prostatic secretions of our cases. METHODS: Five patients with stone-free, acute febrile prostatitis and nine patients with acute episodes of afebrile urinary infection were included. The expressed prostatic secretions (EPS) were collected soon after the acute illnesses subsided after medication administration and they were examined microscopically, bacteriologically, and serologically. First-line medications were cefem antibiotics with conventional doses for febrile cases and low doses for afebrile cases. They were administered for at least 2 weeks. Second-line conventional medication with sulfamethoxazole-trimethoprim or levofloxacin was given only to the patients in whom remaining prostatic infections were revealed. RESULTS: The first-line medications were successful in all patients and they promptly became asymptomatic in 1 week. All the EPS were infected except for two afebrile cases. Prostatic infections were eradicated by second-line conventional medications. In a patient with afebrile prostatitis whose EPS were free of macrophages and immunoglobulin (Ig)M, the eradication of prostatic pathogens was achieved without second-line antibacterial medication. CONCLUSIONS: Bacterial prostatitis could be classified into primary and recurrent chronic infections in each of the febrile (category I) and afebrile (category II) illnesses. A cefem regimen in varying doses was a clue for differential diagnosis as it did not affect the pathogens in the prostatic ducts or acini unless heavy urine reflux occurred in the ductal draining systems. Macrophages and immunoglobulins, especially IgM, in the EPS were useful immunological parameters to differentiate primary and recurrent infections of the prostate. Fluoroquinolones or sulfamethoxazole-trimethoprim should not be employed in acute urinary infections in male patients until the confirmation of prostatic infection to avoid injudicious use of them, which might cause an increasing prevalence of resistant uropathogens in the community. The evacuation of the prostate by repetitive massage seemed to be effective to enhance the prompt eradication of pathogens from the prostatic tissue and to keep patients asymptomatic throughout the course of the disease by preventing tissue pressure elevation.


Subject(s)
Anti-Infective Agents/therapeutic use , Antibodies, Anti-Idiotypic/immunology , Bacterial Infections , Consensus Development Conferences, NIH as Topic , Immunoglobulin M/immunology , Prostatitis , Adult , Aged , Bacterial Infections/classification , Bacterial Infections/drug therapy , Bacterial Infections/immunology , Follow-Up Studies , Humans , Male , Middle Aged , Prognosis , Prostatitis/classification , Prostatitis/drug therapy , Prostatitis/immunology , United States
8.
Int J Antimicrob Agents ; 23 Suppl 1: S41-53, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15037328

ABSTRACT

The efficacy and safety of two oral dosing regimens of gatifloxacin were compared to ciprofloxacin in the treatment of complicated urinary tract infection in a randomised, double-blind multi-centre trial. One thousand one hundred and twenty-three adult patients with complicated urinary tract infection (70%) or pyelonephritis (30%) were initially enrolled, 1122 were treated. Of these, 824 were included in a modified ITT population: gatifloxacin 200 mg (274 patients) or 400 mg (280 patients) once daily or ciprofloxacin 500 mg twice daily for 5-14 days (269 patients). Bacteriological and clinical responses were assessed 7-9 days after the end of treatment (EOT) and 4-6 weeks post-treatment (end of study visit, EOS). The bacteriological response rates per patient at EOT in the gatifloxacin 400 mg, gatifloxacin 200 mg and ciprofloxacin groups were 77% (207/269), 78% (208/268) and 73% (190/259), respectively. At EOS they were slightly lower: 70% (184/262), 71% (176/248) and 69% (174/252), respectively. The clinical responses at EOT were 69% (190/277), 70% (190/273) and 65% (174/266). At EOS they were 71% (193/273), 70% (182/259) and 74% (190/258). The overall eradication rates of initial pathogens at EOT and EOS were 85.3% and 88.4% in the gatifloxacin 400 mg group; 84.1 and 90.1% in the gatifloxacin 200 mg group and 85.1 and 91.4% in the ciprofloxacin group. Both oral regimens of gatifloxacin were as effective as that of ciprofloxacin. All treatment groups showed a similar safety profile, nausea being the most frequently reported adverse event.


Subject(s)
Bacterial Infections/drug therapy , Ciprofloxacin/therapeutic use , Fluoroquinolones/therapeutic use , Pyelonephritis/drug therapy , Urinary Tract Infections/drug therapy , Bacterial Infections/classification , Ciprofloxacin/administration & dosage , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Fluoroquinolones/administration & dosage , Gatifloxacin , Humans , Male , Middle Aged , Treatment Outcome
9.
Urologe A ; 42(2): 238-42, 2003 Feb.
Article in German | MEDLINE | ID: mdl-12607093

ABSTRACT

Chronic pelvic pain syndrome is still an important clinical problem. The NIH prostatitis classification introduced in 1998 for diagnosis and treatment measures is based on extended microbiological analysis of urine and expressed prostate secretion (4-glass test). In 1997 J.C. Nickel proved that the culture and microscopic examination of urine before and after prostatic massage leads to the same results as the 4-glass test. In our prospective study on 143 patients with a diagnosis of chronic prostatitis, we analyzed this statement and came to the same results. We therefore recommend replacing the expensive and time-consuming 4-glass test by a simple preprostatic and postprostatic massage urine culture. Further examinations should only be performed in special cases.


Subject(s)
Bacterial Infections/diagnosis , Bacteriuria/diagnosis , Prostatitis/diagnosis , Adult , Aged , Bacterial Infections/classification , Bacteriuria/classification , Chronic Disease , Colony Count, Microbial , Diagnosis, Differential , Humans , Leukocyte Count , Male , Massage , Middle Aged , Pelvic Pain/etiology , Predictive Value of Tests , Prostate/microbiology , Prostatitis/classification
10.
Annu Rev Microbiol ; 56: 167-85, 2002.
Article in English | MEDLINE | ID: mdl-12142472

ABSTRACT

The fears and predictions of attacks with biological weapons, which were increasing at the close of the twentieth century, were transformed into reality not long after September 11, 2001, when several anthrax-laden letters were sent through the U.S. postal system. The attack challenged our medical preparedness and scientific understanding of the epidemiology of biothreat agents. It is fortunate that this was not a massive aerosol release that could have exposed hundreds of thousands. Rapid diagnoses and medical treatments limited casualties and increased survival rates, but tragically some individuals died of inhalational anthrax. Even as physicians tested new treatment regimes and scientists employed new ways of detecting anthrax and decontaminating the mail, new predictions were made for potentially even more devastating attacks with anthrax, smallpox, plague, tularemia, botulism, or hemorrhagic fever viruses. Fear gripped the nation. Law enforcement sought to find the villain(s) who sent the anthrax letters and to deter future bioterrorist attacks. The biomedical community began to seek new ways of protecting against such future threats of bioterrorism.


Subject(s)
Anthrax/pathology , Bioterrorism , Botulism/pathology , Ciprofloxacin/therapeutic use , Plague/pathology , Smallpox/pathology , Tularemia/pathology , Animals , Anthrax/diagnosis , Anthrax/therapy , Bacterial Infections/classification , Bacterial Infections/prevention & control , Botulism/diagnosis , Botulism/therapy , Cattle , Humans , Plague/diagnosis , Plague/therapy , Smallpox/diagnosis , Smallpox/therapy , Tularemia/diagnosis , Tularemia/therapy
11.
J Foot Ankle Surg ; 33(2): 148-55, 1994.
Article in English | MEDLINE | ID: mdl-8019537

ABSTRACT

Necrotizing fasciitis is a rare, often fatal soft tissue infection. It still remains a confusing entity because of the nomenclature and multiple subtypes described in the past. An interesting case study of a patient with necrotizing fasciitis secondary to nonclostridial gas gangrene is presented. A comprehensive review of necrotizing fasciitis, its disease process and treatment modalities will be discussed.


Subject(s)
Bacterial Infections/classification , Fasciitis/microbiology , Foot Diseases/microbiology , Necrosis/microbiology , Streptococcal Infections/surgery , Bacteria, Anaerobic/isolation & purification , Bacterial Infections/surgery , Bacteroides/isolation & purification , Clavulanic Acids/therapeutic use , Drug Therapy, Combination/therapeutic use , Fasciitis/surgery , Fasciitis/therapy , Foot Diseases/surgery , Foot Ulcer/microbiology , Gangrene/classification , Gangrene/microbiology , Humans , Hyperbaric Oxygenation , Male , Middle Aged , Necrosis/classification , Skin Transplantation , Staphylococcus aureus/isolation & purification , Streptococcus pyogenes/isolation & purification , Ticarcillin/therapeutic use
12.
J Antimicrob Chemother ; 32 Suppl A: 1-9, 1993 Jul.
Article in English | MEDLINE | ID: mdl-8407691

ABSTRACT

Prostatitis remains a challenging condition. The clinical features are often nonspecific while the aetiology and pathogenesis can be diverse and includes inflammatory, obstructive, and/or chemical causes and may also be related to calculi. Four categories are recognized: acute bacterial prostatitis, chronic bacterial prostatitis, non-bacterial prostatitis and prostatodynia. The diagnosis of prostatitis was advanced substantially by the introduction of sequential sampling of urine aliquots following prostatic massage. Bacterial prostatitis is largely associated with the Enterobacteriaceae although Pseudomonas spp., enterococci and Staphylococcus aureus may also be isolated. In chronic bacterial prostatitis a variety of streptococci and anaerobic bacteria may be isolated. Treatment is difficult largely owing to the limited range of agents able to achieve therapeutic concentrations within prostatic fluid, which has a pH lower than that of plasma. Trimethroprim, co-trimoxazole and the tetracyclines have been widely used. The quinolones have recently been shown to diffuse readily into the prostate; ofloxacin and temafloxacin have produced the highest concentrations in prostatic fluid. Antibiotic treatment requires prolonged high dosage and careful monitoring to ensure that bacterial eradication has occurred. Other forms of management have included the judicious use of anti-inflammatory agents and analgesics. In some patients zinc sulphate has proved to be of symptomatic benefit.


Subject(s)
Bacterial Infections , Prostatitis/microbiology , Acute Disease , Adult , Anti-Infective Agents, Urinary/therapeutic use , Bacterial Infections/classification , Bacterial Infections/drug therapy , Bacterial Infections/urine , Chronic Disease , Colony Count, Microbial , Enterobacteriaceae Infections/drug therapy , Enterobacteriaceae Infections/microbiology , Enterobacteriaceae Infections/urine , Humans , Male , Prostatitis/classification , Prostatitis/drug therapy , Prostatitis/urine , Pseudomonas Infections/drug therapy , Pseudomonas Infections/microbiology , Pseudomonas Infections/urine , Staphylococcal Infections/drug therapy , Staphylococcal Infections/microbiology , Staphylococcal Infections/urine , Tetracycline/therapeutic use , Trimethoprim/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL